Quinolone nonsusceptibility among enteric pathogens isolated from international travelers - Foodborne Diseases Active Surveillance Network (FoodNet) and National Antimicrobial Monitoring System (NARMS), 10 United States sites, 2004 - 2014.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Drug Resistance, Microbial* ; Travel* ; Travel-Related Illness*; Foodborne Diseases/*epidemiology ; Foodborne Diseases/*microbiology ; Intestinal Diseases/*epidemiology ; Intestinal Diseases/*microbiology ; Quinolones/*pharmacology; Foodborne Diseases/drug therapy ; Foodborne Diseases/history ; History, 21st Century ; Humans ; Intestinal Diseases/drug therapy ; Intestinal Diseases/history ; Odds Ratio ; Population Surveillance ; United States/epidemiology

Gastrointestinal illnesses are the most frequently diagnosed conditions among returning U.S. travelers. Although most episodes of travelers' diarrhea do not require antibiotic therapy, fluoroquinolones (a type of quinolone antibiotic) are recommended for treatment of moderate and severe travelers' diarrhea as well as many other types of severe infection. To assess associations between quinolone susceptibility and international travel, we linked data about isolate susceptibility in NARMS to cases of enteric infections reported to FoodNet. We categorized isolates as quinolone-nonsusceptible (QNS) if they were resistant or had intermediate susceptibility to ≥1 quinolone. Among 1,726 travel-associated infections reported to FoodNet with antimicrobial susceptibility data in NARMS during 2004-2014, 56% of isolates were quinolone-nonsusceptible, of which most (904/960) were Campylobacter. International travel was associated with >10-fold increased odds of infection with quinolone-nonsusceptible bacteria. Most QNS infections were associated with travel to Latin America and the Caribbean (390/743; 52%); however, the greatest risk of QNS infection was associated with travel to Africa (120 per 1,000,000 passenger journeys). Preventing acquisition and onward transmission of antimicrobial-resistant enteric infections among travelers is critical.
Competing Interests: The authors have declared that no competing interests exist.

Travel Med Infect Dis. 2015 May-Jun;13(3):213-4. (PMID: 26005160)
PLoS One. 2017 Dec 21;12(12):e0189621. (PMID: 29267306)
J Travel Med. 2017 Sep 1;24(5):. (PMID: 28931136)
J Antimicrob Chemother. 2018 May 1;73(5):1368-1388. (PMID: 29514211)
Emerg Infect Dis. 2016 Jan;22(1):117-20. (PMID: 26691898)
Foodborne Pathog Dis. 2018 Jul;15(7):428-436. (PMID: 29624414)
J Travel Med. 2016 Feb 08;23(2):tav024. (PMID: 26858272)
Emerg Infect Dis. 2011 Jan;17(1):7-15. (PMID: 21192848)
MMWR Surveill Summ. 2013 Jul 19;62:1-23. (PMID: 23863769)
Clin Infect Dis. 2012 Jun;54 Suppl 5:S480-7. (PMID: 22572673)
J Antimicrob Chemother. 2018 Feb 1;73(2):287-296. (PMID: 29149266)
MMWR Morb Mortal Wkly Rep. 2015 Apr 3;64(12):318-20. (PMID: 25837241)
Lancet Infect Dis. 2017 Jan;17(1):78-85. (PMID: 27751772)
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2101-2107. (PMID: 28623550)
Travel Med Infect Dis. 2018 May - Jun;23:49-55. (PMID: 29702254)
J Travel Med. 2017 Apr 1;24(suppl_1):S57-S74. (PMID: 28521004)
Travel Med Infect Dis. 2019 Jan - Feb;27:64-71. (PMID: 29894796)
Clin Microbiol Infect. 2018 Aug;24(8):908.e9-908.e16. (PMID: 29133155)
J Travel Med. 2009 May-Jun;16(3):161-71. (PMID: 19538576)
N Engl J Med. 2013 Apr 11;368(15):1461-2. (PMID: 23574140)

0 (Quinolones)

Date Created: 20191205 Date Completed: 20200330 Latest Revision: 20200330

20240104

PMC6892504

10.1371/journal.pone.0225800

31800600